for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sumitomo Dainippon Pharma Co Ltd

4506.T

Latest Trade

2,155.00JPY

Change

18.00(+0.84%)

Volume

966,700

Today's Range

2,133.00

 - 

2,167.00

52 Week Range

1,661.00

 - 

3,885.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,137.00
Open
2,137.00
Volume
966,700
3M AVG Volume
24.03
Today's High
2,167.00
Today's Low
2,133.00
52 Week High
3,885.00
52 Week Low
1,661.00
Shares Out (MIL)
397.30
Market Cap (MIL)
869,411.80
Forward P/E
18.10
Dividend (Yield %)
1.51

Next Event

Q3 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Release

Latest Developments

More

Sunovion Resubmits New Drug Application For Apomorphine Sublingual Film

Sumitomo Dainippon Pharma & Roivant Sciences Sign Definitive Agreement For Strategic Alliance

Sumitomo Dainippon Pharma Withdraws Offer To Acquire Australia's Cynata Therapeutics

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sumitomo Dainippon Pharma Co Ltd

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other Overseas division is involved in the development of its products in Europe. The Company is also engaged in the manufacture, purchase, sale and supply of food materials and additives, chemical products, veterinary drugs, diagnostic products and inspection services of clinical pathology for animal, the manufacture of extracts, as well as the storage, delivery and clinical inspection of drugs.

Industry

Biotechnology & Drugs

Contact Info

2-6-8, Dosho-machi, Chuo-ku

+81.6.62035321

https://www.ds-pharma.co.jp/

Executive Leadership

Masayo Tada

Chairman of the Board, Representative Director

Hiroshi Nomura

President, Representative Director

Hitoshi Odagiri

Managing Executive Officer, Chief Director of Sales, Head of Japan Business Unit, Director

Yoshiharu Ikeda

Managing Executive Officer, Chief Director of Production, Deputy Head of Japan Business Unit

Kazuo Koshiya

Managing Executive Officer, Global Head of Oncology

Key Stats

3.33 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.4K

2018

0.5K

2019

0.5K

2020(E)

0.5K
EPS (JPY)

2017

72.970

2018

134.530

2019

122.390

2020(E)

117.417
Price To Earnings (TTM)
16.99
Price To Sales (TTM)
1.87
Price To Book (MRQ)
1.70
Price To Cash Flow (TTM)
13.05
Total Debt To Equity (MRQ)
5.76
LT Debt To Equity (MRQ)
5.18
Return on Investment (TTM)
8.13
Return on Equity (TTM)
6.22

Latest News

Latest News

Sumitomo Dainippon Pharma investing $3 billion in Swiss Roivant in overseas push

Japan's Sumitomo Dainippon Pharma Co <4506.T> will pay $3 billion for a 10% stake in Swiss drugmaker Roivant Sciences Ltd and interests in five of its biopharmaceutical businesses, the two companies said on Friday.

Sumitomo Dainippon Pharma to invest $3 bln in Swiss Roivant

Japan's Sumitomo Dainippon Pharma Co will pay $3 billion for a 10% stake in Swiss drugmaker Roivant Sciences Ltd and interests in five of its biopharmaceutical businesses, the two companies said on Friday.

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases

BRIEF-Sumitomo Dainippon Pharma says change of president

* Says it appoints Masayo Tada as chairman of the board, and Hiroshi Nomura as president, effective April 1

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

BRIEF-Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.

* Says it filed patent infringement lawsuits jointly with its U.S. subsidiary, Sunovion Pharmaceuticals Inc. on February 13(U.S. Eastern Time) in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd. and in the U.S. District Court for...

BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film

* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD...

BRIEF-Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan

* POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN

BRIEF-Sumitomo Dainippon Pharma says result of early-retirement program

* Says 86 employees took up the offer of the early-retirement program announced on Sept. 27

BRIEF-Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD

* SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD

BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe

* Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co

BRIEF-Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin

* Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries

BRIEF-Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia

* SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES

BRIEF-Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement

* Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR)

BRIEF-R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I

BRIEF-Sumitomo Dainippon Pharma to offer early-retirement program

* Says it will offer an early-retirement program to employees, who are above 45 years old and continuous service of above 5 years as of March 31, 2018, and employees is members of manufacturing division as of Sept. 1, 2016

BRIEF-Sumitomo Dainippon Pharma U.S.-based unit enters agreement to divest asthma and allergy products to Covis pharma

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. has entered into a definitive agreement to divest the U.S. market rights of Sunovion’s three ciclesonide products to Covis Pharma B.V. on July 13(US Eastern Time)

BRIEF- Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow® (glycopyrrolate) for the long-term, maintenance treatment of airflow...

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor...

BRIEF- Sumitomo Dainippon Pharma announces application of International Financial Reporting Standards

* Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up